SCHEMBL2824683

SCHEMBL2824683

O=C(CCc1ccccc1)N1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
KMT2A Q03164 3/20 1.00
MEN1 O00255 2/20 1.00
ME2 P23368 1/20 0.78
ME1 P48163 1/20 0.78
ME3 Q16798 1/20 0.78
GFER P55789 2/20 0.76
HTR7 P34969 3/20 0.71
ALDH1A1 P00352 4/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
HTR1A P08908 1/20 0.70
GRM5 P41594 1/20 0.67
ATM Q13315 1/20 0.67
NPSR1 Q6W5P4 2/20 0.62
CYP2C19 P33261 1/20 0.62
HTT P42858 1/20 0.62
NPC1 O15118 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
FKBP1A P62942 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796071 0.89 MAPT (0.80) MAPTKMT2AMEN1ME2ME1
SCHEMBL3797901 0.87 ME2 (1.00) MAPTKMT2AMEN1ME2ME1
SCHEMBL2471006 0.87 MAPT (0.75) MAPTKMT2AMEN1ME2ME1
SCHEMBL8091444 0.86 MEN1 (0.80) MAPTKMT2AMEN1ME2ME1
SCHEMBL3799766 0.86 GFER (1.00) MAPTKMT2AMEN1ME2ME1
SCHEMBL11076871 0.86 GFER (0.89) MAPTKMT2AMEN1ME2ME1
SCHEMBL16501806 0.85 MEN1 (0.78) MAPTKMT2AMEN1ME2ME1
SCHEMBL2820899 0.85 KMT2A (0.74) MAPTKMT2AMEN1ME2ME1
SCHEMBL7131839 0.83 NPC1 (0.86) MAPTKMT2AMEN1ME2ME1
SCHEMBL3796309 0.83 GFER (0.74) MAPTKMT2AMEN1ME2ME1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238633-B2 Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-01-19 US disclosed
US-8901116-B2 Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-12-02 US disclosed
US-20140243352-A1 METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-08-28 US disclosed
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-03-27 US disclosed
US-8648083-B2 Method of treating diabetic hyperlipidemia or hyperlipidemia with carbamoyloxy arylalkanoyl arylpiperazine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-02-11 US disclosed
US-8541409-B2 Carbamoyloxy arylalkanoyl arylpiperazine analgesics SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-09-24 US disclosed
US-20130131081-A1 PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-05-23 US disclosed
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO. LTD. (KR) 2010-06-24 US disclosed
EP-2155736-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK Holdings Co., Ltd. (KR) 2010-02-24 EP disclosed
WO-2008140198-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO., LTD. (KR) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND HTR5A, OPRD1, OPRL1 MAPT 3315/4885KMT2A 1354/4885MEN1 4789/4885
US-20130131081-A1 PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND LIPG, CETP, GPR119 MAPT 1539/4885KMT2A 3036/4885MEN1 4779/4885
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND HTR5A, OPRL1, HDAC3 MAPT 2882/4885KMT2A 1204/4885MEN1 4723/4885
US-20140243352-A1 METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS LIPG, DPP7, IAPP MAPT 3107/4885KMT2A 2791/4885MEN1 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.